CN112384246B - 适体制剂 - Google Patents

适体制剂 Download PDF

Info

Publication number
CN112384246B
CN112384246B CN201980043745.7A CN201980043745A CN112384246B CN 112384246 B CN112384246 B CN 112384246B CN 201980043745 A CN201980043745 A CN 201980043745A CN 112384246 B CN112384246 B CN 112384246B
Authority
CN
China
Prior art keywords
aptamer
fgf2
nucleotides
aqueous liquid
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980043745.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN112384246A (zh
Inventor
中村义一
秋田一雅
优素福·阿里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribomic Inc
Original Assignee
Ribomic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribomic Inc filed Critical Ribomic Inc
Publication of CN112384246A publication Critical patent/CN112384246A/zh
Application granted granted Critical
Publication of CN112384246B publication Critical patent/CN112384246B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN201980043745.7A 2018-06-29 2019-06-28 适体制剂 Active CN112384246B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018124390 2018-06-29
JP2018-124390 2018-06-29
PCT/JP2019/025766 WO2020004607A1 (ja) 2018-06-29 2019-06-28 アプタマー製剤

Publications (2)

Publication Number Publication Date
CN112384246A CN112384246A (zh) 2021-02-19
CN112384246B true CN112384246B (zh) 2025-02-21

Family

ID=68986754

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980043745.7A Active CN112384246B (zh) 2018-06-29 2019-06-28 适体制剂

Country Status (14)

Country Link
US (1) US20210269802A1 (enExample)
EP (1) EP3815715B1 (enExample)
JP (1) JP7340264B2 (enExample)
KR (1) KR102841342B1 (enExample)
CN (1) CN112384246B (enExample)
AU (1) AU2019292134B2 (enExample)
BR (1) BR112020026634A2 (enExample)
CA (1) CA3105002A1 (enExample)
ES (1) ES2992308T3 (enExample)
IL (1) IL279595B1 (enExample)
MX (1) MX2020014124A (enExample)
SG (1) SG11202012933QA (enExample)
TW (1) TWI845521B (enExample)
WO (1) WO2020004607A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4122471A4 (en) * 2020-02-06 2025-02-19 Ribomic Inc THERAPEUTIC AGENT FOR SUBRETINAL HYPERREFLECTIVE MATERIAL OR RETINAL DISORDERS ASSOCIATED WITH SUBRETINAL HYPERREFLECTIVE MATERIAL

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009118108A1 (en) * 2008-03-26 2009-10-01 Merck Patent Gmbh Method of long term storage of substrate-coupled beads
CN106103719A (zh) * 2014-03-24 2016-11-09 力博美科股份有限公司 针对fgf2的适体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5847086A (en) * 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
CA2669523C (en) * 2006-11-14 2016-06-21 Ribomic Inc. Aptamer against midkine and use thereof
CN101317820B (zh) * 2007-04-19 2012-02-29 中国人民解放军军事医学科学院毒物药物研究所 生物亲和性配体分子介导的靶向脂质体，其制 备及其应用
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
US9052323B2 (en) * 2009-08-27 2015-06-09 The University Of Kansas Osmolyte mixture for protein stabilization
JP5899550B2 (ja) 2010-02-12 2016-04-06 株式会社リボミック Ｆｇｆ２に対するアプタマー及びその使用
WO2014116789A1 (en) * 2013-01-25 2014-07-31 Thymon, Llc Immunogenic and prophylactic compositions, methods of making same, and method for treating and preventing tnf-mediated disease and hiv-1 infection
US11807857B2 (en) * 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
JP2018124390A (ja) 2017-01-31 2018-08-09 株式会社沖データ 画像形成装置及び定着制御方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009118108A1 (en) * 2008-03-26 2009-10-01 Merck Patent Gmbh Method of long term storage of substrate-coupled beads
CN106103719A (zh) * 2014-03-24 2016-11-09 力博美科股份有限公司 针对fgf2的适体及其应用

Also Published As

Publication number Publication date
AU2019292134A1 (en) 2021-02-11
KR102841342B1 (ko) 2025-07-31
SG11202012933QA (en) 2021-01-28
TW202012625A (zh) 2020-04-01
EP3815715A1 (en) 2021-05-05
AU2019292134B2 (en) 2025-07-10
CN112384246A (zh) 2021-02-19
US20210269802A1 (en) 2021-09-02
EP3815715A4 (en) 2022-03-16
WO2020004607A1 (ja) 2020-01-02
MX2020014124A (es) 2021-05-31
EP3815715C0 (en) 2024-09-11
JPWO2020004607A1 (ja) 2021-07-15
ES2992308T3 (es) 2024-12-11
KR20210025083A (ko) 2021-03-08
JP7340264B2 (ja) 2023-09-07
IL279595A (en) 2021-03-01
IL279595B1 (en) 2025-11-01
CA3105002A1 (en) 2020-01-02
BR112020026634A2 (pt) 2021-04-06
EP3815715B1 (en) 2024-09-11
TWI845521B (zh) 2024-06-21

Similar Documents

Publication Publication Date Title
TWI823866B (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
US20230078200A1 (en) RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
CN103946381B (zh) Ngf适体及其应用
ES2375631T3 (es) Compuesto oligómero antisentido sustituido con inosina, conjugado con un péptido, y método de preparación.
JP2023158192A (ja) アルファ－ＥＮａＣの発現を阻害するためのＲＮＡｉ剤、および使用方法
CN114222820A (zh) 用于治疗α-1抗胰蛋白酶缺乏症(AATD)的方法
JP2023501246A (ja) ベータＥＮａＣの発現を阻害するＲＮＡｉ剤、その組成物および使用方法
JP2023519246A (ja) ＰＮＰＬＡ３の発現を阻害するためのＲＮＡｉ薬、その医薬組成物、及び使用方法
CN112384246B (zh) 适体制剂
EP4267191A1 (en) Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
HK40046627A (en) Aptamer preparation
EP4122471A1 (en) Therapeutic agent for subretinal hyperreflective material or retinal disorders accompanying subretinal hyperreflective material
US12110492B2 (en) RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use
RU2847618C2 (ru) Способы лечения дефицита альфа-1-антитрипсина (aatd)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant